UNASSIGNED: The Ethos system has enabled online adaptive radiotherapy (oART) by implementing an automated treatment planning system (aTPS) for both intensity-modulated radiotherapy (IMRT) and volumetric modulated arc radiotherapy (VMAT) plan creation. The purpose of this study is to evaluate the quality of aTPS plans in the pelvic region.
UNASSIGNED: Sixty patients with anal (n = 20), rectal (n = 20) or prostate (n = 20) cancer were retrospectively re-planned with the aTPS. Three IMRT (7-, 9- and 12-field) and two VMAT (2 and 3 arc) automatically generated plans (APs) were created per patient. The duration of the automated plan generation was registered. The best IMRT-AP and VMAT-AP for each patient were selected based on target coverage and dose to organs at risk (OARs). The AP quality was analyzed and compared to corresponding clinically accepted and manually generated VMAT plans (MPs) using several clinically relevant dose metrics. Calculation-based pre-treatment plan quality assurance (QA) was performed for all plans.
UNASSIGNED: The median total duration to generate the five APs with the aTPS was 55 min, 39 min and 35 min for anal, prostate and rectal plans, respectively. The target coverage and the OAR sparing were equivalent for IMRT-APs and VMAT-MPs, while VMAT-Aps.demonstrated lower target dose homogeneity and higher dose to some OARs. Both conformity and homogeneity index were equivalent (rectal) or better (anal and prostate) for IMRT-APs compared to VMAT-MPs. All plans passed the patient-specific QA tolerance limit.
UNASSIGNED: The aTPS generates plans comparable to MPs within a short time-frame which is highly relevant for oART treatments.

Varian Ethos, a new treatment platform, is capable of automatically generating treatment plans for initial planning and for online, adaptive planning, using an intelligent optimization engine (IOE). The primary purpose of this study is to assess the efficacy of Varian Ethos IOE for auto-planning and intercompare different treatment modalities within the Ethos treatment planning system (TPS). A total of 36 retrospective prostate and proximal seminal vesicles cases were selected for this study. The prescription dose was 50.4 Gy in 28 fractions to the proximal seminal vesicles, with a simultaneous integrated boost of 70 Gy to the prostate gland. Based on RT intent, three treatment plans were auto-generated in the Ethos TPS and were exported to the Eclipse TPS for intercomparison with the Eclipse treatment plan. When normalized for the same planning target volume (PTV) coverage, Ethos plans Dmax% were 108.1 ± 1.2%, 108.4 ± 1.6%, and 109.6 ± 2.0%, for the 9-field IMRT, 12-field IMRT, and 2-full arc VMAT plans, respectively. This compared well with Eclipse plan Dmax% values, which was 108.8 ± 1.4%. OAR indices were also evaluated for Ethos plans using Radiation Therapy Oncology Group report 0415 as a guide and were found to be comparable to each other and the Eclipse plans. While all Ethos plans were comparable, we found that, in general, the Ethos 12-field IMRT plans met most of the dosimetric goals for treatment. Also, Ethos IOE consistently generated dosimetrically hotter VMAT plans versus IMRT plans. On average, Ethos TPS took 13 min to generate 2-full arc VMAT plans, compared to 5 min for 12-field IMRT plans. Varian Ethos TPS can generate multiple treatment plans in an efficient time frame and the quality of the plans could be deemed clinically acceptable when compared to manually generated treatment plans.